ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) announced today the publication of Phase 2 data for retigabine, a first-in-class neuronal potassium channel opener, in Neurology, a leading independent, scientific journal. The authors concluded that retigabine was efficacious with a demonstrated reduction in monthly seizure rates in this study. Two pivotal Phase 3 trials (RESTORE1 and RESTORE2) are currently underway to further investigate the efficacy and safety of retigabine as an adjunctive treatment for partial-onset seizures in patients with refractory epilepsy.
